NL1037721C2 - AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. - Google Patents
AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. Download PDFInfo
- Publication number
- NL1037721C2 NL1037721C2 NL1037721A NL1037721A NL1037721C2 NL 1037721 C2 NL1037721 C2 NL 1037721C2 NL 1037721 A NL1037721 A NL 1037721A NL 1037721 A NL1037721 A NL 1037721A NL 1037721 C2 NL1037721 C2 NL 1037721C2
- Authority
- NL
- Netherlands
- Prior art keywords
- medication
- light
- visible
- influence
- prevented
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
Description
Axiaal doorgesneden buis welke door middel van een krimpkous of anderszins om een injectiespuit wordt aangebracht waardoor de inhoud daarvan niet zichtbaar is en de invloed van licht en dergelijke op de medicatie wordt voorkomen.Axially cut tube which is fitted around a syringe by means of a heat shrink or otherwise, as a result of which the contents thereof are not visible and the influence of light and the like on the medication is prevented.
_ De hierboven beschreven afscherming van de inhoud van een injectiespuit is van belang 0 bij dubbelblinde onderzoeken zodat zowel de toediener als de patiënt niet kunnen waarnemen of daadwerkelijk de medicatie dan wel een placebo of anderszins wordt ingespoten.The shielding of the contents of a syringe described above is important in double-blind examinations so that both the operator and the patient cannot see whether the medication or a placebo or otherwise is being injected.
10 1 Bovendien is de afscherming van de inhoud van belang bij medicaties die gevoelig zijn voor licht en dergelijke waardoor een langere tijd beschikbaar is tussen de productie en de toediening hetgeen sterke kostenbesparingen met zich meebrengt.In addition, the shielding of the content is important for medications that are sensitive to light and the like, whereby a longer time is available between production and administration, which entails considerable cost savings.
10377211037721
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1037721A NL1037721C2 (en) | 2010-02-16 | 2010-02-16 | AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1037721 | 2010-02-16 | ||
NL1037721A NL1037721C2 (en) | 2010-02-16 | 2010-02-16 | AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. |
Publications (1)
Publication Number | Publication Date |
---|---|
NL1037721C2 true NL1037721C2 (en) | 2011-08-17 |
Family
ID=42801074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL1037721A NL1037721C2 (en) | 2010-02-16 | 2010-02-16 | AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. |
Country Status (1)
Country | Link |
---|---|
NL (1) | NL1037721C2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4048997A (en) * | 1976-11-01 | 1977-09-20 | Mpl, Inc. | Syringe with actinic radiation protection |
KR20040012189A (en) * | 2002-08-01 | 2004-02-11 | 소광섭 | Syringe for shading liquid therein from light |
WO2007067653A2 (en) * | 2005-12-05 | 2007-06-14 | Lifeline Cell Technology | Cell culture medium container assembly |
-
2010
- 2010-02-16 NL NL1037721A patent/NL1037721C2/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4048997A (en) * | 1976-11-01 | 1977-09-20 | Mpl, Inc. | Syringe with actinic radiation protection |
KR20040012189A (en) * | 2002-08-01 | 2004-02-11 | 소광섭 | Syringe for shading liquid therein from light |
WO2007067653A2 (en) * | 2005-12-05 | 2007-06-14 | Lifeline Cell Technology | Cell culture medium container assembly |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huys et al. | European drug shortages: a call for action! | |
NL1037721C2 (en) | AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. | |
Shahnazari | Ethics and nursing care for dying patient | |
Basu et al. | Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin e in non-alcoholic fatty liver disease-a randomized open label placebo controlled clinical prospective trial (captive) | |
Kotecki et al. | Update of the T-DIS randomized Phase II trial: trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS) | |
Mehrabani et al. | Afsantin (Artemisia absinthium L.) from the perspective of modern and traditional Persian medicine | |
Missri et al. | 22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis | |
Stroes et al. | Omega-3 carboxylic acids in severe hypertriglyceridemia: EVOLVE II study results | |
Bancroft | Governments and insulin: Overcoming barriers to fulfilling the right to an essential medicine | |
Hajizadeh Moghaddam et al. | Neuroprotective effect of Quince leaf hydroalcoholic extract on intracerebroventricular streptozotocin-induced oxidative stress in cortical tissue of rat brain | |
Machiels et al. | Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) | |
Dhangar et al. | Formulation and Evaluation of Proniosomal Gel in Ocular Drug | |
برکتين et al. | Adherence of treatment of schizophrenia to the published treatment guidelines in university hospital | |
Del Paggio et al. | Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit? | |
CN203302550U (en) | Vacuum seal cosmetic bottle | |
Skowronska et al. | Role of Endothelial NMDA Receptors in the Pathogenesis of Hepatic Encephalopathy | |
Su-rong et al. | Introduction to UK occupational health reporting network system run by University of Manchester | |
Grothey et al. | Phase III Randomized, Placebo (Pl)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1 | |
Fuesl | Allergic reaction: case report | |
requires Kayexalate | drug interaction studies | |
Wahowiak | APHA cites dangers of liquid nicotine | |
Takeuchi et al. | Treatment After Discontuance of Regorafenib for Colorectal Cancer | |
Kalinkin et al. | On pathoautokinesis of hyperlipoproteidemia and its clinical significance | |
Neutel et al. | Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: teamsta severe HTN study | |
Ng et al. | Impact of adjuvant anthracycline-based and taxane-based chemotherapy on plasma VEGF levels and cognitive function in early-stage breast cancer patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Lapsed because of non-payment of the annual fee |
Effective date: 20160301 |